Compare
Advanced Biomed Inc. vs YD Bio Ltd vs Aclarion, Inc. vs BioNexus Gene Lab Corp
| Latest fiscal year | Advanced Biomed Inc. ADVBRevenue covers only part of its income (partial revenue) | YD Bio Ltd YDES | Aclarion, Inc. ACON | BioNexus Gene Lab Corp BGLC |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $596.8K | $75.7K | $7.42M |
| Revenue growth (YoY) | n/a | +16.9% | +65.6% | -21.9% |
| Gross margin | n/a | 28.1% | 9.0% | 14.6% |
| Operating margin | n/a | -883.3% | n/m | -39.9% |
| Net margin | n/a | n/m | n/m | -40.2% |
| Net income | $6.68M | -$8.31M | -$7.23M | -$2.98M |
| EPS (Diluted) | $5.33 | -$0.12 | -$13.61 | n/a |
| Operating cash flow | -$1.95M | -$6.60M | -$7.16M | -$1.84M |
| Free cash flow | n/a | -$8.04M | -$7.19M | -$1.88M |
| Cash & equivalents | n/a | $6.01M | $12.02M | $2.49M |
| Total assets | $13.75M | $13.78M | $13.67M | $9.25M |
| Total liabilities | $1.47M | $16.64M | $837.3K | $637.9K |
| Shareholders' equity | $12.28M | -$2.86M | $12.84M | $8.61M |
| Return on year-end equity | 54.4% | n/a | -56.4% | -34.6% |
| Shares outstanding | 1.65M | 70.79M | 854.4K | 2.42M |
Revenue, most recent five fiscal years
| Fiscal year | Advanced Biomed Inc. | YD Bio Ltd | Aclarion, Inc. | BioNexus Gene Lab Corp |
|---|---|---|---|---|
| Latest | n/a | $596.8K Ended 2025-12-31 | $75.7K Ended 2025-12-31 | $7.42M Ended 2025-12-31 |
| 1 year earlier | n/a | $510.4K Ended 2024-12-31 | $45.7K Ended 2024-12-31 | $9.51M Ended 2024-12-31 |
| 2 years earlier | n/a | $350.1K Ended 2023-12-31 | $75.4K Ended 2023-12-31 | $9.77M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $60.4K Ended 2022-12-31 | $10.93M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $60.3K Ended 2021-12-31 | $13.36M Ended 2021-12-31 |